BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Zacks Research

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report issued on Wednesday, Zacks reports.

A number of other analysts also recently weighed in on the stock. Guggenheim began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 price target on the stock. JPMorgan Chase & Co. began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 target price for the company. HC Wainwright assumed coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $35.00 target price on the stock. Leerink Partners began coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $36.00 price target for the company. Finally, Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BlossomHill Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $32.20.

BlossomHill Therapeutics Trading Up 3.3%

BlossomHill Therapeutics stock opened at $20.02 on Wednesday. BlossomHill Therapeutics has a 1 year low of $15.25 and a 1 year high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In related news, Director Orbimed Advisors Llc purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director directly owned 2,714,279 shares of the company’s stock, valued at $43,428,464. This represents a 29.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Vincent Liptak acquired 2,200 shares of the stock in a transaction dated Monday, August 10th. The shares were bought at an average cost of $16.00 per share, with a total value of $35,200.00. Following the transaction, the general counsel directly owned 111,412 shares of the company’s stock, valued at $1,782,592. This represents a 2.01% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

More BlossomHill Therapeutics News

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: Leerink Partners initiated coverage with an Outperform rating and a $36 price target, while HC Wainwright began coverage with a Buy rating and a $35 target. These targets imply substantial potential appreciation if the company executes successfully. BlossomHill Therapeutics Research Coverage Started at Leerink Partners BlossomHill Therapeutics Research Coverage Started at HC Wainwright
• Positive Sentiment: Guggenheim also initiated coverage with a Buy rating and a $30 price target. The cluster of bullish initiations provides broader sell-side validation for BLSM. BlossomHill Therapeutics Research Coverage Started at Guggenheim
• Positive Sentiment: Additional coverage was initiated by JPMorgan Chase and Lifesci Capital, increasing institutional visibility for the clinical-stage cancer drug developer.
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could give investors more information about its small-molecule oncology pipeline and development progress. BlossomHill Therapeutics Conference Presentations
• Neutral Sentiment: HC Wainwright continues to forecast losses, including fiscal 2026 EPS of approximately ($3.71) and fiscal 2027 EPS of ($2.99). However, its estimates improve through 2027, supporting the firm’s Buy rating and $35 price objective.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.